Lymphatic filariasis

Improved availability of new test to enhance global lymphatic filariasis elimination

5 February 2016 ¦ Geneva −− A new diagnostic test enabling countries to determine when to stop large-scale treatment of populations to eliminate lymphatic filariasis is now available. WHO is coordinating the procurement and supply of the new test for use in its Global Programme to Eliminate Lymphatic Filariasis (GPELF).

The Filariasis Test Strip (FTS) is a new point-of-care rapid diagnostic test designed to detect in human blood the antigen of the major species of filarial worm (Wuchereria bancrofti) that causes lymphatic filariasis.

WHO welcomes Nobel Prize in Physiology or Medicine 2015 for discoveries of drugs against tropical diseases

05 October 2015 | Geneva −− WHO welcomes the decision to award the Nobel Prize in Physiology or Medicine for discoveries of drugs that have radically improved treatment against tropical diseases such as malaria, onchocerciasis and lymphatic filariasis.

The prize for artemisinin is a tribute to the contribution of the Chinese scientific community in the fight against malaria. Artemisinin compounds have become the mainstay of malaria treatment over the past 15 years.

What is lymphatic filariasis

© WHO

Lymphatic filariasis, commonly known as elephantiasis, is a neglected tropical disease. Infection occurs when filarial parasites are transmitted to humans through mosquitoes.

fact buffet

Treatments

5.6 BillionCumulative treatments delivered

Preventive chemotherapy database

Impact

315 MillionPopulation no longer requiring treatment in 44 countries

Training in monitoring and epidemiological assessment of mass drug administration

Patients

40 MillionNumber of affected patients

Morbidity management and disability prevention